IP Library Granted Patent US 9,981,018
Granted Patent B2
US 9,981,018 · App. 13/709,918 · Granted May 29, 2018

Compositions and methods for modulating toll-like receptor 2 activation

Inventor: Tatiana Byzova (Pepper Pike, OH)
Assignee: The Cleveland Clinic Foundation
A61K38/385A61K8/4913A61K47/64A61Q7/00A61Q19/00A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,981,018
App. No.
13/709,918
Granted
May 29, 2018
Kind
B2
Abstract

A method of promoting hair growth of a subject includes administering to follicle cells of the subject a therapeutically effective amount of a TLR2 agonist that promotes TLR2 activation and hair growth of the subject.

Claims (20)

1. A method of promoting hair growth at a skin wound site of a mammalian subject, comprising:

administering to the skin wound site of the mammalian subject a therapeutically effective amount of a TLR2 agonist that promotes TLR2 activation and hair growth of the mammalian subject, the TLR2 agonist comprising a carboxyethylpyrrole (CEP) adduct or pharmaceutically acceptable salts thereof.

2. The method of claim 1 , wherein the therapeutically effective amount is the amount required to increase hair follicle density at the skin wound site of the subject.

3. The method of claim 1 , the CEP adduct having the following formula:

wherein X is a peptide, polypeptide, small molecule, or polymer, and is bound to the amine of the CEP pyrrole or pharmaceutically acceptable salts thereof.

4. The method of claim 3 , wherein X is selected from the group consisting of mouse serum albumin and human serum albumin.

5. A method of promoting hair growth at a skin wound site of a mammalian subject, comprising:

administering to the skin wound site of the mammalian subject a therapeutically effective amount of a TLR2 agonist that promotes TLR2 activation and hair growth at the skin wound site of the mammalian subject, the TLR2 agonist comprising a carboxyethylpyrrole (CEP) adduct having the following formula:

wherein X is selected from the group consisting of a dipeptide, mouse serum albumin and human serum albumin, and is bound to the amine of the CEP pyrrole or pharmaceutically acceptable salts thereof.

6. The method of claim 5 , wherein the therapeutically effective amount is the amount required to increase hair follicle density at the skin wound site of the subject.

7. A topical formulation for promoting hair growth at a skin wound site in a mammalian subject, the topical formulation comprising:

a therapeutically effective amount of a carboxyethylpyrrole (CEP) adduct that promotes TLR2 activation and at least one carrier or pharmaceutically acceptable salts thereof, the topical formulation when administered to the skin wound site of the mammalian subject promoting hair growth at the skin wound site.

8. The topical formulation of claim 7 , wherein the therapeutically effective amount is the amount required to increase hair follicle density at the skin wound site of the subject.

9. The topical formulation of claim 7 , the CEP adduct having the following formula:

wherein X is a peptide, dipeptide, polypeptide, small molecule, or polymer, and is bound to the amine of the CEP pyrrole and or pharmaceutically acceptable salts thereof.

10. The topical formulation of claim 9 , wherein X is selected from the group consisting of mouse serum albumin and human serum albumin.

11. A topical formulation for promoting hair growth at a skin wound site in a mammalian subject, the topical formulation comprising:

a therapeutically effective amount of a carboxyethylpyrrole (CEP) adduct that promotes TLR2 activation and at least one carrier, the topical formulation when administered to the skin wound site of the subject promoting hair growth at the skin wound site, the CEP adduct having the following formula:

wherein X is selected from the group consisting of a dipeptide, mouse serum albumin and human serum albumin, and is bound to the amine of the CEP pyrrole or pharmaceutically acceptable salts thereof.

12. The topical formulation of claim 11 , wherein the therapeutically effective amount is the amount required to increase hair follicle density at the skin wound site of the subject.

Assignments (3)
CONFIRMATORY LICENSE Recorded May 4, 2017
From: CLEVELAND CLINIC FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 042402/0366 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2013
From: BYZOVA, TATIANA
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 031255/0783 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2013
From: BYZOVA, TATIANA
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 031249/0223 →
Continuity (3)
Continuation PCTUS2011039562 · Jun 8, 2011
Provisional Application 61352651 · Jun 8, 2010
Related Publication 20130102536A1 · Apr 25, 2013